Tor Ole Klemsdal

Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

Paul M. Ridker, Jean MacFadyen, Tom Thurén et al. · The Lancet · 2017 · 1.3K citations · Full text

Inflammation, Allergy, Lung Inflammation +11

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

Paul M. Ridker, Jean MacFadyen, Peter Libby et al. · The Lancet · 2017 · 847 citations · Full text

Cardiovascular Toxicity, C-reactive Protein Reduction, Cardiovascular Disease +8

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

Carel W. le Roux, Arne Astrup, Ken Fujioka et al. · The Lancet · 2017 · 813 citations

Obesity, Metabolic Syndrome, Nutrition +8

A randomized clinical trial on<i>n</i>-3 polyunsaturated fatty acids supplementation and all-cause mortality in elderly men at high cardiovascular risk

Gunnar Einvik, Tor Ole Klemsdal, Leiv Sandvik et al. · European Journal of Cardiovascular Prevention & Rehabilitation · 2010 · 92 citations · Full text

Effect of diet or very long chain  -3 fatty acids on progression of atherosclerosis, evaluated by carotid plaques, intima-media thickness and by pulse wave propagation in elderly men with hypercholesterolaemia

Elsa M. Hjerkinn, Michael Abdelnoor, L. Breivik et al. · European Journal of Cardiovascular Prevention & Rehabilitation · 2006 · 91 citations · Full text